

Reliable, Compliant
Commercial Manufacturing
BioCina delivers worry-free global supply through disciplined GMP execution, robust quality systems, and seamless scale-up, ensuring your therapies reach patients safely and on time.
Commercial-Grade Release at Scale

Drug Substance Batch Release
GMP-released microbial, pDNA, mRNA, and LNP drug substance with full batch records and Certificate of Analysis.
01

Drug Product Batch Release
GMP-released fill-finish across BFS, sterile vial filling, PFS, cartridge, oral liquid, cytotoxic as well as controlled substance programs. Annual capacity exceeding 225 million units, approved by FDA, TGA, EMA, Health Canada, and ANVISA.
02

On-Time In-Full Delivery
Greater than 95% on-time, in-full delivery target across clinical and commercial programs, supported by demand-aligned production planning, committed capacity agreements, proactive quality oversight and dedicated program managers.
03

Lifecycle Supply Management
Annual Product Reviews prepared to ICH Q10. Continued Process Verification provides ongoing statistical assurance that your commercial process remains in a validated state of control. Qualified vendor and material programs and business continuity protocols protect supply integrity across both sites.
04

Continuously Maintained to Licensure Standards
Every batch is manufactured against approved master batch records with full QC testing, formal deviation management, and QA-reviewed disposition. Real-time process monitoring and contamination control are embedded across all campaigns in our multi-product manufacturing environment. QP batch release for EU-bound programs is available.
Quality systems are maintained to commercial licensure standards at all times. TGA standards are harmonized with FDA and EMA through PIC/S membership, meaning BioCina-generated GMP data supports approvals across major global markets.
An electronic quality management system (eQMS), validated to 21 CFR Part 11 and EU Annex 11, governs deviation management, change control, training, and documentation at each manufacturing site, ensuring data integrity and full traceability at every stage.
BioCina's quality framework and manufacturing SOPs were established under a US FDA pre-approval inspection with zero observations. Our sites hold active TGA licenses and have maintained zero critical observations across all GMP inspection years, including a 2025 TGA inspection under the BioCina name.
Drug substance manufactured at our Adelaide biologics facility transfers directly to our sterile fill-finish site. It is managed by one project management interface, and one accountable team from fermentation through to finished product.
Filing-Ready From First Batch

CMC Section Authoring
On-site authoring covering Module 2.3 and Module 3 CMC content for IND, CTN, BLA, NDA, and MAA submissions across FDA, TGA, EMA, Health Canada, and ANVISA regulatory pathways.
01

Submission and Filing Support
Preparation of Drug Master Files, site transfer supplements including Prior Approval Supplement and CBE-30, and post-approval CMC variations supporting changes to registered manufacturing processes.
02

Inspection Preparation
and Support
Gap assessments and pre-inspection readiness activities against current FDA, EMA, and TGA expectations, with manufacturing facilities inspection-ready at all times.
03

Post-Approval CMC Management
Annual Product Review authoring to ICH Q10, post-approval change assessment, and CMC lifecycle management for commercial products.
04

One Manufacturing Site, Global Regulatory Reach
CMC packages are filing-ready from the first batch, reducing time between batch release and submission readiness.
TGA standards are harmonized with FDA and EMA through PIC/S. BioCina-generated manufacturing data, GMP certificates, and analytical packages support clinical trials and product approvals across the US, Europe, and key global markets without duplication.
Programs manufactured at BioCina can enter Australia's Clinical Trial Notification pathway, allowing first-in-human studies to begin without a full IND equivalent. Australian clinical trial data is generated under ICH-aligned standards and has been accepted to support international regulatory submissions.
Processes Designed for Scale
Upstream Process Development
QbD-aligned fermentation optimization across fed-batch and batch modes, with scale-up bridging from development scale through to GMP production.
Downstream Process Development
Full downstream scope covering product recovery, refolding, chromatography, TFF, and hollow-fiber filtration, all designed for commercial scale-up. Inclusion body refolding supported by a dedicated DOE-driven platform and a 3,000 L refold tank. Continuous cell lysis scalable to 500 L fermentation.
Nucleic Acid Process Development
Dedicated pDNA purification laboratory with continuous flow cell lysis, CIM monolith chromatography for high supercoiled content and purity, and TFF for concentration and buffer exchange.
Process Characterization
Lorem ipsum

Scale-Up Ready by Design
Quality Target Product Profile First
Every program begins with a Quality Target Product Profile, establishing a shared understanding of your molecule, critical quality attributes, and the control strategy required to reach scale reliably.
Analytical Development in Parallel
Lorem ipsum
Closed, Single-Use Systems
Lorem ipsum
Scale-Up by Design
Lorem ipsum

Ready to Start Your Manufacturing Program?
Connect with our team to discuss reliable, compliant commercial supply for your therapy.

